Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Barinthus Biotherapeutics (BRNS) Operating Expenses (2020 - 2026)

Barinthus Biotherapeutics (BRNS) has disclosed Operating Expenses for 7 consecutive years, with $6.1 million as the latest value for Q1 2026.

  • For Q1 2026, Operating Expenses fell 70.75% year-over-year to $6.1 million; the TTM value through Mar 2026 reached $56.3 million, down 36.02%, while the annual FY2025 figure was $71.1 million, 15.52% down from the prior year.
  • Operating Expenses hit $6.1 million in Q1 2026 for Barinthus Biotherapeutics, down from $11.6 million in the prior quarter.
  • Across five years, Operating Expenses topped out at $31.6 million in Q4 2022 and bottomed at -$1.1 million in Q3 2022.
  • Average Operating Expenses over 5 years is $17.3 million, with a median of $18.9 million recorded in 2024.
  • Year-over-year, Operating Expenses tumbled 119.28% in 2022 and then skyrocketed 1603.73% in 2023.
  • Barinthus Biotherapeutics' Operating Expenses stood at $31.6 million in 2022, then tumbled by 36.65% to $20.0 million in 2023, then rose by 17.94% to $23.6 million in 2024, then plummeted by 50.91% to $11.6 million in 2025, then crashed by 47.11% to $6.1 million in 2026.
  • According to Business Quant data, Operating Expenses over the past three periods came in at $6.1 million, $11.6 million, and $15.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.